Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From KEDI Nvidia Fixed Tech100 Index (KNVDT100)
4/29/2026, 12:00:00 AM
Announced in its Q1 2026 report that the FDA approved extending the dosing intervals for EYLEA HD up to every 20 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Medium importance assigned due to expanded label for a key product, estimated to impact price by ≥5% scheduled.
Korean Translation
2026년 1분기 보고서에서 FDA가 습성 연령 관련 황반변성(wAMD) 및 당뇨병성 황반부종(DME) 환자를 대상으로 아일리아 HD(EYLEA HD)의 투여 간격을 최대 20주까지 연장하는 것을 승인했다고 발표함. 주요 제품의 적응증 확대로 5% 이상의 주가 영향이 예상됨.
Related Recent Events
Telefonaktiebolaget LM Ericsson (publ) (ERIC) · Earnings Release
Q3 2026 earnings release scheduled.
10/15/2026, 12:00:00 AM
ASML Holding NV (ASML) · Earnings Release
ASML is scheduled to release its Q2 2026 financial results on 2026-07-15. The company guided for Q2 sales between €8.4 billion and €9.0 billion, with an estimated price impact of ≥5%, scheduled.
7/15/2026, 12:00:00 AM
Telefonaktiebolaget LM Ericsson (publ) (ERIC) · Earnings Release
Q2 2026 earnings release scheduled.
7/14/2026, 12:00:00 AM
CrowdStrike Holdings Inc (CRWD) · Other
2026 Annual Meeting of Stockholders to be held virtually on 2026-06-17. Medium importance due to ≥5% price impact scheduled.
6/17/2026, 12:00:00 AM
Adobe Inc (ADBE) · Earnings Release
Adobe's Q2 2026 earnings release, which typically results in a medium price impact of 5%, is scheduled.
6/11/2026, 12:00:00 AM
CrowdStrike Holdings Inc (CRWD) · Earnings Release
Q1 fiscal 2027 earnings release scheduled for 2026-06-09. Analysts forecast EPS of $1.07. Low importance due to ≥1% price impact forecasted.
6/9/2026, 12:00:00 AM